The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface

Hong Liu1, Jie Zheng1* and Aihua Liao2*

1Department of Reproduction, Maternal and Child Health Hospital of Hubei Province, Affiliated in Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Institute of Reproductive Health, Center for Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

The immune microenvironment at the maternal-fetal interface was determined by the crosstalk between the trophoblast and maternal-derived cells, which dynamically changed during the whole gestation. Trophoblasts act as innate immune cells and dialogue with maternal-derived cells to ensure early embryonic development, depending on the local immune microenvironment. Therefore, dysfunctions in trophoblasts and maternal decidual cells contribute to pregnancy complications, especially recurrent pregnancy loss in early pregnancy. Since many unknown regulatory factors still affect the complex immune status, exploring new potential aspects that could influence early pregnancy is essential. RNA methylation plays an important role in contributing to the transcriptional regulation of various cells. Sufficient studies have shown the crucial roles of N6-methyladenosine (m6A)- and m6A-associated-regulators in embryogenesis during implantation. They are also essential in regulating innate and adaptive immune cells and the immune response and shaping the local and systemic immune microenvironment. However, the function of m6A modifications at the maternal-fetal interface still lacks wide research. This review highlights the critical functions of m6A in early embryonic development, summarizes the reported research on m6A in regulating immune cells and tumor immune microenvironment, and identifies the potential value of m6A modifications in shaping trophoblasts, decidual immune cells, and the microenvironment at the maternal-fetal interface. The m6A modifications are more likely to contribute to embryogenesis, placentation and shape the immune microenvironment at the maternal-fetal interface. Uncovering these crucial regulatory mechanisms could provide novel therapeutic targets for RNA methylation in early pregnancy.

KEYWORDS
m6A methylation, embryo development, immune tolerance, maternal-fetal interface, early pregnancy
Introduction

Most mammalian genomes undergo RNA transcription, and many RNA transcripts can never be translated into proteins (1), which may lead to functional defects. RNA is not only an essential intermediate in the flux from DNA to proteins but also a regulatory molecule for fundamental cellular processes, the dysfunction of which contributes to important pathological processes (2). The coding and noncoding transcriptomes are widely and dynamically regulated by chemical modification, which adds new modifications of complexity and functionality to the emerging roles of RNAs in physiological and pathological conditions (3). Covalent modifications sense the changing environment directly and rapidly without changing the DNA and RNA sequences (4). In contrast to the epigenetic modifications on DNA and histones that work at the transcriptional level, RNA methylation has a notable effect on gene regulation at the posttranscriptional level (5). RNA modifications affect transcripts by altering the charge, base-pair potential, secondary structure and RNA–protein interactions, which, in turn, regulates gene expression via RNA processing, localization, translation and degradation (3). N6-methyladenosine (m6A) is the most abundant internal mRNA modification. Identifying of the proteins that mediate m6A modifications has elucidated the roles of mRNA modifications in nearly every aspect of the mRNA life cycle, as well as various cellular, developmental, and disease processes (3). In mammals, approximately 0.1%- 0.6% of adenines undergo m6A modification, with an average of 3-5 methylated sites in each mRNA. Remarkably, m6A modifications can be deposited onto transcripts in tissue- and cell-type-specific manners (6).

The m6A modifications commonly occur in yeast, plants, flies, bacteria, humans and other mammals, which implicates its multiple functions in RNA, including precursor mRNA (pre-mRNA) splicing, mRNA translation, stability, structure, export and decay, implying an association with several cellular processes, such as cell differentiation and reprogramming, further contributing to various human diseases (reviewed in (7)). For m6A detection, methods, including analytical chemistry, high-throughput sequencing, m6A-CLIP and miCLIP, have emerged to determine the specific methylation sites and the modification fractions at these sites to promote biological studies of RNA modifications (3, 8–11), which provided the available ways to study the roles of m6A modification proteins in physical and pathological processes.

Similar to DNA methylation, the deposition and removal of mRNA methylation also depend on a multicomponent methyltransferases, mainly methyltransferase-like 3 (METTL3), METTL14, Wilms’ tumor 1-associated protein (WTAP), RNA-binding motif proteins 15 (RBM15s), virlike m6A methyltransferase associated (VIRMA/KIAA1429), zinc finger CCCH-Type containing 13 (ZC3H13) and METTL16 (13–19). METTL3 is the most important component of the m6A methyltransferase complex (MTC) and highly conserved in eukaryotes from yeast to mammals (20); METTL3 forms a stable heterodimer complex regulated by WTAP and catalyzes the transfer of meth1 groups (13, 21). Similar to WTAP, RBM15s have no catalytic function but bind to METTL3 and WTAP to guide these two proteins to specific RNA sites for m6A modification. KIAA1429-mediated m6A methylation of mRNAs takes place near the 3’-UTR and the stop codon (22). m6A modification occurs when METTL3 and METTL14 are recruited into the nucleus (14). Only METTL3 has methyltransferase activity in the MTC. METTL16 encodes S-adenosylmethionine (SAM) synthase and is expressed in most cells. However, METTL16-mediated m6A sites were located in introns or intron–exon boundaries, which is different from the common m6A sites in UTRs (19). The m6A demethylases as “erasers” make the m6A methylation dynamic and reversible, which could be passively removed from the transcriptome via degradation of the modified RNA or active demethylation by the m6A demethylases fat mass and obesity-associated (FTO) or a-ketoglutarate-dependent dioxygenase alkB homolog 5 (ALKB5), both belonging to the AlkB family of dioxygenases known to demethylate N-methylated nucleic acids (23, 24). FTO was the first demethylase discovered in 2011 (23). The ALKBH5 catalytic domain can demethylate m6A-containing single-stranded RNA (ssRNA) and single-stranded DNA (ssDNA) (25).

The discovery of reader proteins has made great progress in elucidating the impact of m6A methylation in mammalian cells. Different ‘readers’ with different cellular localizations influence almost all aspects of RNA metabolism, such as YT521-B homology domain family proteins (YTHDFs), insulin-like growth factor 2 mRNA-binding proteins (IGF2BP), eukaryotic translation initiation factor 3 (eIF3) and heterogeneous nuclear ribonucleoproteins (HNRNPs) (26–29). Proteins with YTH domains located in the cytoplasm (YTHDF1, YTHDF2 and YTHDF3) and nuclei (YTHDC1 and YTHDC2) directly recognize m6A marks (27, 30), which promote the degradation and translation of m6A-modified RNA. In contrast to YTHDFs, IGF2BP promote the stability and storage of their target mRNAs in a m6A-dependent manner under normal stress conditions and therefore affect gene expression output (28). eIF3 directly binds a single 5’ UTR m6A and recruits the 43S complex to initiate translation in a cap-dependent manner (26). Numerous studies have shown that m6A modifications play essential roles in multiple biological
and pathological processes: hematopoietic development, central nervous and system development, the adaptive and innate immune system, carcinogenesis and the tumor microenvironment, as well as gametogenesis and early embryo development, the dysfunction of which generally results in various diseases by abnormal m6A modifications of the target genes (31) (Figure 1). Currently, with the development of assisted reproductive technology (ART), which helps to exclude abnormalities in the embryo, there remains the occurrence of recurrent pregnancy loss (RPL) in child-bearing women (32). Embryo implantation into the endometrium successfully relies on strict and coordinated regulation of trophoblasts derived from the fetus and decidual stromal cells and immune cells derived from the maternal sides (33). Crosstalk could be regulated by molecules associated with implantation, including hormones, signaling molecules, transcription factors and cytokines (34). However, the occurrence of RPL remains high, and more efforts should be made to discover the mystery of embryo implantation. Emerging studies emphasize the essential roles of m6A modifications in embryo implantation, while their roles in trophoblasts and immune tolerance at the maternal-fetal interface are worthy of further investigation.

Successful blastocyst implantation was first established by normal embryo development after fertilization. Its further development relies on the dynamically coordinated balance between the fetal-derived invading trophoblasts and the receptive maternal decidua (35). Once implantation is initiated, the trophoblasts, originating from the outer layer of the blastocyst, will differentiate into invasive extravillous trophoblasts (EVTs) to attach and invade the maternal decidua and therefore promote placentation (36), making the first contact with the maternal immune system. The placenta not only mediates the hormonal, nutritional and oxygen support to the fetus but also plays an essential immunoregulatory role at the maternal-fetal interface (37). Blastocysts that take paternal antigens as semiallogeneic to the maternal side can be recognized and accepted by the immunosuppressive maternal immune system (38). After normal implantation, the implantation sites are infiltrated with diverse immune cells, which are mainly characterized by an anti-inflammatory Th2-type immune microenvironment (39). Previously, embryo quality was shown to contribute to adverse pregnancy complications. ART tools make the selection of high-quality embryos available; however, implantation rates and successful pregnancy with ART are still relatively low. This indicated that uterine receptivity might also play a crucial role in the establishment of normal pregnancy (40). Diverse mechanisms, including cytokine/chemokine and hormonal signaling as well as DNA modifications, contribute to the pathology of pregnancy complications (40), which is attributed to the abnormal gene expression of cytokines/chemokines and abnormal signaling in a specific time and space during placentation and further fetal development.

![Overview of the reversible m6A RNA modifications and related functions.](image-url)

**FIGURE 1**
Overview of the reversible m6A RNA modifications and related functions. m6A modifications are regulated by m6A writers (METTL3, METTL14, RBM15s and WATP) and readers (FTO and ALKBH5). m6A methylation is recognized by different readers (YTHDC1-2, YTHDF1-3 and EIF3) by regulating RNA splicing, exportation, translation, degradation, stabilization and storage.
Early mammalian embryos are capable of strong pluripotent stemness, which could be reprogrammed by epigenetic modifications. m6A modification is highly conserved from yeast to mammals and can regulate gene expression output, determine stem cell fate and cell differentiation, and further shape the local microenvironment. Recent studies have shown that m6A modifications are associated with animal reproductive processes, including gametogenesis, maternal-zygote transition (MZT) and early embryonic development (41–45). In addition, m6A modifications also play an essential role in fine-tuning the immune response, including innate and adaptive immune responses and immune system development (8). Here, we reviewed the potential roles and novel insights of m6A methylation in embryo development and immune tolerance during early pregnancy during maternal-fetal tolerance.

m6A functions in preimplantation embryogenesis

After fertilization, the newly generated zygote sustains a transcriptionally quiescent state and initiates early maternally programmed embryogenesis, following zygote genome activation (ZGA) with a clearance of maternal stores (RNA and DNA), which is termed the maternal-to-zygote transition (MZT) (46). The most important biological process, early embryonic development, is generally determined by a programmed transition into a totipotent and pluripotent embryonic state, followed by cell fate decisions and lineage-specific differentiation (47). Early embryogenesis relies on maternally inherited mRNA. Recently, emerging studies have reported that the epitranscriptomic mark m6A and its cofactors play critical roles in ensuring gene expression in an appropriate time and space in both preimplantation and postimplantation embryonic development (46, 47). In the murine preimplantation embryo, germinal vesicle (GV) oocyte-specific knockdown (KD) of Mettl3 inhibited oocyte maturation and the MZT by disrupting maternal mRNA degradation (41). Additionally, Mettl3 is mainly located in the intracisternal A particle (IAP)-type family of endogenous retroviruses. Mettl3 knockout (KO) in mice blocked the integrity of multiple heterochromatin marks on METTL3-targeted IAPs. Mechanistically, the RNA transcripts in METTL3-bound IAPs are related to m6A-methylated chromatin, which is regulated by the m6A reader YTHDF1. This interaction, in turn, promotes the association of METTL3 with chromatin. Furthermore, METTL3 also interacts with the H3K9me3 methyltransferase SETDB1 and its cofactor TRIM28 (48). These results suggest an important role of METTL3-targeted IAP integrity in mouse embryonic stem cells. Downregulation of the m6A reader HnRNPA2/B1, which is regulated by Mettl3, blocked mouse embryonic development from the 4-cell stage by altering global gene expression involving the transcription, translation, cell cycle, embryonic stem cell differentiation, and RNA methylation pathways in HnRNPA2/B1 KD blastocysts. Similar results were found in Mettl3 KD blastocysts, which also showed that HnRNPA2/B1 is regulated in a Mettl3-dependent manner (49). In Mettl14 arginine 255 (R255me) mutant mice, embryonic stem cells (mESCs) led to decreased global mRNA m6A levels and preferentially affected endoderm differentiation in mESCs. Mettl14 R255me markedly enhances the interaction of Mettl3/Mettl14 with WTAP and binds to the substrate RNA. Moreover, protein arginine N-methyltransferase 1 (PRMT1) regulates Mettl14 at R255, which highlights the communication between protein and RNA methylation in regulating gene expression (50). Knockdown of Mettl3 and Mettl14 in mESCs led to similar phenotypes, with a lack of m6A RNA methylation and loss of self-renewal capability (27).

WTAP, as part of the MTC, is essential for the blastocyst rate and global m6A levels of porcine early embryonic development, indicating the indispensable role of WTAP in porcine embryo development (51). An mRNA interactome capture study in zebrafish embryos identified the dramatic translocation of HnRNPA1 accompanied by the movement from cytoplasmic to nuclear RNA targets and other pre-mRNA splicing factors to the nucleus in a transcription-dependent manner, indicating that HnRNPA1 RNA-binding activities regulated RNA metabolism during early embryo development in a spatial and temporal manner (52). Accurately, one-third of zebrafish maternal mRNA is m6A modified, and m6A-binding protein promotes the clearance of maternal mRNAs, the removal of which slows down the decay of m6A-modified maternal mRNA and impairs ZGA, therefore blocking the initiation of the timely MZT and cell cycle and contributing to the overall delay of larval life (43). Additionally, the m6A reader protein YTHDF1-3, as a maternal mRNA-binding partner, was highly expressed in the zebrafish MZT process (3), suggesting that YTHDF protein-mediated m6A modification may regulate the MZT process. m6A-methylated maternal mRNA degradation impedes YTHDF2-deficient zebrafish embryos and therefore delays the timely MZT and leads to developmental interruption during the larval period (43). In addition, it was also reported that the m6A reader YTHDF2 is essential for oocyte maturation and embryo development (43, 53). The oocyte-specific deletion of YTHDF2 in mice also impeded the degradation of maternal mRNAs, thereby delaying the ZGA process. These results suggest that YTHDF2 plays important roles in the transcriptome transition by mediating m6A-dependent mRNA degradation. Similar to YTHDF2, the oocyte-specific deletion of VIRMA contributes to female-specific infertility in mice, which inhibits oocyte maturation by regulating pre-mRNA alternative splicing (54). In human ESCs, the ALKBH5 catalytic domain is fused to targeted RNA m6A erasure (TRME) and therefore
demethylates the target m6A sites and increases mRNA stability with limited off-target effects (55). However, the role of VIRMA in early embryonic development remains unknown and requires further investigation.

In contrast to YTHDF2 that promotes mRNA decay, IGF2BPs could work as a new class of cytoplasmic m6A readers that regulate the stability and storage of mRNAs (28). Downregulation of Igf2bp1 in zebrafish parthenogenetic activation (PA) embryos decreased the cleavage and blastula rates, which induced cell apoptosis and could be rescued by augmenting the miR-670 inhibitor (56). Maternal deletion of Igf2bp2 (also called IMP2) results in murine early embryo development arrest at the 2-cell stage in vitro by decreasing the expression of Ccar1 and Rps14, both of which are essential for early embryonic developmental competence (57). However, the role of IGF2BP2 in regulating mRNA stability and degradation in ZGA as a m6A reader still needs to be clarified. Deletion of maternal Igf2bp3 degraded maternal mRNAs prior to MZT and resulted in severe developmental defects of abnormal cytoskeleton organization and cell division and destabilized the Igf2bp3-bound mRNAs. Interestingly, Igf2bp3 overexpression in wild-type embryos also causes a developmental delay. These results indicate the important functions of Igf2bp3 in regulating early zebrafish embryogenesis by binding and stabilizing maternal mRNAs (58). The above findings suggested that the function of IGF2BP3 is different from that of YTHDF2, but both are indispensable for early embryogenesis in various species (Figure 2).

**m6A functions in postimplantation embryogenesis**

After implantation, the blastocyst attaches to the uterus and initiates differentiation and development. The ectoderm of the blastocyst is the trophoblast stem cells, which differentiate into multiple trophoblast subsets and therefore promote placentation. The inner cell mass transitions from naïve state pluripotency to primed state pluripotency and is required for organogenesis and individual formation (47). A number of studies have reported that m6A determines the fate of embryonic stem cells (ESCs), losing m6A modifications causes pluripotent stem cells to display a state of hyperpluripotency and cannot differentiate into lineages, thus contributing to embryonic lethality (55, 59). Mechanistically, METTL3−/− ESCs exhibited poor differentiation potential that prevented KO teratomas from forming the three germ layers. The abnormal expression of NANOG from E5.5 to E7.5 in epiblasts led to embryonic lethality. Mettl3 and Mettl14 KO mice both exhibited embryonic lethality at E6.5 (59, 60). These findings indicate the important role of METTL3/METTL14 in early embryogenesis. Another m6A writer, METTL16, regulates human MAT2A, and increasing METTL16 binding to the methionine...
adenosyltransferase 2A (MAT2A) 3’UTR could promote efficient splicing in a hairpin (hp1) m6A-dependent manner (19). However, the m6A modifications on MAT2A were recognized by YTHDC1 for mRNA degradation (61). Although normal morphology and genotyping ratios were observed in E2.5 and E3.5 blastocysts from WT and Mettl16 KO mice, only 1.9% Mettl16 KO embryos at E6.5 could be found in the Mettl16−/− mouse model, indicating that METTL16 deletion led to embryo lethality around implantation (42). Interestingly, the most decreased gene in E2.5 KO embryos was Mat2a, suggesting that Mettl16 and Mat2a are essential for early embryonic development. Apart from METTLs, another m6A writer, WATP-deficient ESCs, failed to differentiate into endoderm and mesoderm. In addition, deficiency of WATP in embryos results in abnormal egg cylinders at the gastrulation stage and causes embryonic lethality at E10.5 in mice (62).

However, the relevant mechanisms need further exploration. YTHDC1, as the only nuclear reader, regulates the alternative polyadenylation (APA), AS and nuclear export of m6A-modified mRNAs in mouse oocytes. In addition, YTHDC1 is essential for early embryonic development (63). These results indicated that YTHDC1 is not only critical for gametogenesis but also important for the viability of early embryo development. Interestingly, no colonies were found in hnRNPA2/B1 mouse KO blastocysts. Nonetheless, knockdown of hnRNPA2/B1 impeded embryonic development after the 4-cell stage and blocked further development, and a similar phenotype was observed in Mettl3 KD embryos. Furthermore, Mettl3 KD blastocysts showed enhanced mislocalization of hnRNPA2/B1 and reduced m6A methylation, which suggested that hnRNPA2/B1 is important for early embryogenesis by Mettl3-dependent m6A RNA methylation (49). Deficiency of m6A methylation writers, easers and readers generally leads to embryo lethality postimplantation. However, these mutants focus on the embryo itself and not the placenta. The results of deciphering the developmental disorders programmed for placental phenotypes in embryonic lethal and subviable mouse knockout lines showed that 68% of KO lines mainly exhibited placental dysmorphologies (64). Early embryo lethality is closely associated with placental malformation, which strongly correlates with abnormal brain, heart and vascular development (64). The critical role of the placenta in pregnancy was determined by the trophoblast lineage. In preeclampsia (PE), METTL3 and m6A methylation were upregulated in the placental trophoblast (65). The maturation of miR-497/195-5P mediated by METTL3 impeded trophoblast migration and invasion by targeting WWP1 in PE patients (66). In addition, the RNA demethylase FTO and HLA-G were significantly decreased in the trophoblasts of spontaneous abortion (SA) patients, and the mRNA expression of VEGFA, VEGFR and MMP2 bound to YTHDF2 also decreased in SA patients, which indicated that FTO in the chorionic villi promotes immune tolerance and angiogenesis at the maternal-fetal interface due to aberrant methylation and oxidative stress and therefore leads to the occurrence of SA (67). Downregulation of ALKBH5 demethylase KDM3B mediated activated leukocyte cell adhesion molecule (ALCAM) by increasing PARG mRNA m6A modification and activating the Wnt/β-catenin pathway, in turn relieving PE progression (68). In addition, Xiaocui Li et al. reported that global mRNA m6A methylation was significantly decreased in villi from RPL patients without affecting ALKBH5 expression. Besides, ALKBH5 KD in villous explants enhanced trophoblast invasion by upregulating the half-life of cysteine-rich angiogenic inducer 61 (CYR61) mRNA (69) (Figure 2). Although some m6A modifications are reported to be associated with the differentiation and function of trophoblasts, more explorations are needed to elucidate the other m6A enzymes in the biological and immunoregulatory functions of trophoblasts and provide broad RNA epigenetic regulatory patterns in physical and pathological pregnancies.

m6A functions in the innate immune response

Innate immunity provides the first line of defense against infections in a nonspecific manner. The innate immune cells at the maternal-fetal interface consist of macrophages (MΦs), natural killer (NK) cells and dendritic cells (DCs), which can sense invading pathogens and exogenous RNAs rapidly and thus respond in a timely manner to foreign pathogens (70). Innate immune cells comprise large populations of immune cells at the maternal-fetal interface (35). DC cells are the main antigen presentation cells (APCs) that can activate T cells and are equipped with the capacity to effectively take up, process and present antigens on the cell surface (71). Emerging studies have shown that m6A modification and m6A-associated proteins mediate innate immunity by regulating the recognition and responses to foreign pathogens, unmodified tRNAs, exogenous RNAs and aberrant endogenous RNAs. The recognition of foreign pathogens depends on several pattern-recognition receptors, such as plasma membrane receptors (Toll-like receptors, TLRs) and cytosolic sensors (RIG-I-like receptors, RIG-I and NLR proteins) (72). Kariko K et al. in 2005 reported that m6A modification decreased TLR3, TLR7, or TLR8 activation in monocyte-derived DCs (MDDCs), which was the first time that the regulatory effect on the process of RNA recognition was presented (73). Once RNA recognition occurs, the innate immune response immediately initiates and releases multiple cytokines, such as type I interferons (IFNs) and interferon-stimulated genes (ISGs) (74, 75). METTL14 depletion inhibited viral reproduction and promoted dDNA- or HCMV-induced IFNB1 mRNA accumulation, while
ALKBH5 depletion exhibited the opposite effect \((75)\) (Figure 3A). The RNA helicase DDX46 demethylates the antiviral proteins MAVS, TRAF3 and TRAF6 by recruiting ALBKH5 \((76)\) (Figure 3C). hnRNPA2B1 recognizes viral DNA and facilitates the m6A modification nucleocytoplasmic trafficking of CGAS, IFI16, and STING mRNAs by preventing FTO-mediated demethylation, thereby amplifying IFN production and enhancing the antiviral effect on HSV-1 infection \((77)\) (Figure 3D). In addition, m6A modification also mediates the metabolic program to promote host immunity against viral infection. Downregulation of ALBKHS increases the m6A modifications on the mRNA of a-ketoglutarate dehydrogenase (OGDH) and reduces its mRNA stability and protein expression, which inhibits viral replication \((78)\) (Figure 3B). These studies suggest that m6A modifications exert a contributory effect on antiviral responses by targeting antiviral-specific genes and proteins and reprogramming the metabolic state of the host. In addition, mounting evidence has shown that m6A methylation plays a critical role in DC activation and function. Mettl3-specific depletion in DCs results in delayed maturation in response to lipopolysaccharide (LPS) and impaired phenotypic and functional maturation of DCs. Mechanistically, the expression of the costimulatory molecules CD40 and CD80, the TLR4 signaling adaptor Tirap and the cytokine IL-12 decreased with a low capacity to stimulate T-cell responses.
in Ythdf1−/− mice, implicating YTHDF1 as a therapeutic target in cancer immunotherapy (79). These findings indicate that m6A methylation and its related proteins play major roles in the maturation and activation of DCs and promote the initiation of the adaptive immune response through antigen cross-presentation.

Macrophages serve as another main component of innate immune cells. RNA binding protein-focused CRISPR screening results showed that m6A writers were the top candidate genes in regulating LPS-activated macrophages. Mettl3 ablation macrophages produced little TNF-α with LPS stimulation (80) (Figure 4A). However, Mettl3 downregulation in macrophages significantly increased the proinflammatory cytokines TNF-α, IL-6 and NO. Mechanically, Mettl3 KO in macrophages promoted the expression and stability of NOD1 and RIPK2, which were mediated by YTHDF1 and YTHDF2, respectively (81) (Figure 4A). Additionally, Mettl3 and YTHDF2 cooperatively regulate PGC-1α mRNA degradation in oxidized low-density lipoprotein (ox-LDL)-induced monocytes (82) (Figure 4A). Mettl3 promotes the ox-LDL-induced inflammatory response in macrophages by modifying STAT1 mRNA, thereby polarizing macrophages to the M1 phenotype (83). The deletion of Mettl3 in myeloid cells promotes tumor growth and metastasis in vivo. Mechanistically, Mettl3-deficient mice showed increased M1/M2-like tumor-associated macrophage and regulatory T (Treg) cell infiltration in the local tumor microenvironment due to the impairment of YTHDF1-mediated SPRED2, which enhances the activation of nuclear factor κB (NF-κB) and STAT3 via the ERK pathway and consequently leads to tumor growth and metastasis. Furthermore, PD-1 checkpoint blockade was partially decreased in Mettl3-deficient mice, indicating the important role of Mettl3 in tumor immunotherapy (84). Additionally, myeloid lineage-restricted deletion of Mettl3 protects mice from age-related and diet-induced development of innate immunity-driven nonalcoholic fatty liver disease (NAFLD).

![Figure 4](https://example.com/figure4.png)

**Figure 4**

Macrophage polarization was modified by m6A methylation in different environments. (A) Mettl3 ablation macrophages produced little TNF-α with LPS stimulation. Mettl3 downregulation in macrophages significantly increased the proinflammatory cytokines TNF-α, IL-6 and NO by increasing NOD1 and RIPK2 via YTHDF1 and YTHDF2, respectively. Mettl3 and YTHDF2 cooperatively degraded PGC-1α mRNA in ox-LDL-treated monocytes. (B) Myeloid lineage-restricted Mettl3 deletion protected mice from age-related and diet-induced development of innate immunity-driven nonalcoholic fatty liver disease (NAFLD) and obesity by decreasing mTOR expression and the NF-κB pathway by targeting DDIT4. (C) FTO deficiency inhibited both M1 and M2 polarization by suppressing the NF-κB signaling pathway and decreasing the stability of STAT and PPAR-γ via YTHDF2 involvement, therefore blocking macrophage activation. (D) The loss of Mettl14 decreased the demethylase Soc1 mRNA to activate TLR4/NF-κB signaling. In addition, IGF2BP2 KO macrophages were refractory to IL-4-induced activation to regulate the switch of M1 to M2 subtypes in a m6A-dependent manner.
and obesity. Mettl3 deficiency results in a notable increase in DNA damage inducible transcript 4 (DDIT4) mRNA. The decrease in mammalian target of rapamycin (mTOR) and NF-κB pathway activity in Mettl3-deficient macrophages could be restored by DDIT4 KD (85) (Figure 4B). These findings demonstrate the contribution of Mettl3-mediated m6A modification of DDIT4 to macrophage metabolic reprogramming in NAFLD and obesity. Lihui Dong et al. reported that macrophage-specific knockout of the m6A methyltransferase Mettl14 drives CD8+ T-cell differentiation with a dysfunctional trajectory, impairing CD8+ T cells to eliminate tumors (86). Silencing of the m6A eraser FTO markedly inhibited both M1 and M2 polarization by suppressing the NF-κB signaling pathway and decreasing the stability of STAT and PPAR-γ via YTHDF2 involvement, therefore blocking macrophage activation (87, 88) (Figure 4C). Mettl14 ablation in myeloid cells contributes to acute bacterial infection in mice by the continuous production of proinflammatory cytokines, which can be rescued by forced expression of Socs 1 in macrophages depleted of Mettl14 or YTHDF1. Loss of Mettl14 decreases demethylase expression, and Socs1 mRNA overactivates TLR4/NF-κB signaling. These findings highlight that m6A methylation-mediated SOCS1 expression is essential for the negative feedback control of macrophages on bacterial infection (89). YTHDF1 KD macrophages in rats improved the secretion of anti-inflammatory cytokines, highlighting the protective role of YTHDF1 KD macrophages in severe sepsis rats with ECMO (90). YTHDF2 KD in the mouse macrophage cell line Raw264.7 enhanced osteoclast formation and bone resorption (91). The m6A reader IGF2BP2-abated macrophages showed enhanced M1 polarization and promoted dextran sulfate sodium-induced colitis development. IGF2BP2−/− macrophages are refractory to IL-4-induced activation by targeting tuberous sclerosis 1 to regulate the switch of M1 to M2 subtypes in a m6A-dependent manner, which indicates the key role of IGF2BP2 in the regulation of macrophages (92) (Figure 4D). These results indicated that the differentiation and function of macrophages could be regulated by m6A methylation.

NK cells are a large population of innate lymphocytes involved in antitumour and antiviral immunity. The m6A reader YTHDF2 is markedly increased in NK cells when activated by cytokines, tumors and virus infection, which mediates NK-cell antitumour and terminal maturation related to modulating NK-cell trafficking and regulating Eomes, respectively, losing which affects the antitumour and antiviral function of NK cells in vivo. Mechanistically, YTHDF2 promotes the effector function of NK cells and is essential for IL-15-mediated NK-cell survival and proliferation by the STAT5-YTHDF2 positive feedback loop, highlighting the novel biological role of YTHDF2 in NK cells in antitumour immunity (93) (Figure 5A). In addition, inactivation of Mettl3 in NK cells changed the hemostasis, infiltration and function of NK cells in the tumor microenvironment, leading to accelerated tumor growth and short lifespan in mice by modifying SHP-2 mRNA, which rendered NK cells hyporesponsive to IL-15 (94) (Figure 5B). However, the role of m6A modifications in the development and function of macrophages and NK cells remains limited and is worthy of more focus and investigation.

m6A functions in the adaptive immune response

Adaptive immunity could be special in the clearance of specific pathogens, which are mainly mediated by the activation of antigen-specific T/B lymphocytes, and finally
establish long-term immunological memory against the given antigen. Recently, an increasing number of studies have shown that m6A exerts an important effect on adaptive immunity and modulates the differentiation and function of different subsets of T cells (70). Val1, expressed in all immune cells, is used as Cre recombinase with the Val1 promoter in studying the immune response. However, METTL3 deficiency in Val1-Cre mice led to nonviable progeny, indicating the critical role of METTL3 in immune cells. While CD4, CD11C and Foxp3 were used to construct cell-specific transgenic mice (95), a large amount of m6A was still detectable (78, 96), which reflected incomplete METTL3 deletion.

The generation and maturation of CD4+ T cells in the thymus highly depend on the T-cell receptor (TCR) and multiple costimulatory signals. Initially, deficiency of METTL3 in CD4+ T cells did not affect the generation, maturation or capacity to respond to TCR stimulation in vitro, which indicated that the basic TCR signals and downstream signal transduction did not depend on m6A methylation in vitro (96). In CD4+ T-cell-specific Mettl3 KO mice, the proportion of naïve cells was higher, while the proportion of activating CD4+ T cells was lower than that in WT mice, and Mettl3 KO mice developed spontaneous colitis, indicating that m6A helped to keep naïve cells quiescent. A similar phenotype was observed in Mettl14 KO mice (96).

IL-7 is essential for homeostatic proliferation and long-term survival of naïve T cells (97). Likewise, the naïve T cells in Mettl3 KO mice show a striking similarity to CD4+ T cells transferred to IL-7-deficient mice (98). The IL-7 receptor suppresses cytokine signaling of SOCS1 targets (98). Members of the SOCS family, including Socs1, Socs3 and Cish, bind the cytokine receptor and prevent STAT5 activation and downstream signaling (99) (Figure 6A). The SOCS genes were marked by m6A and showed slower mRNA degradation and higher protein expression in Mettl3-deficient T helper cells, which possibly impeded signal transduction through IL-7R (96). However, the role of m6A methylation in the response to cognate antigen recognition in vitro and pathogens in vivo cannot be excluded (8). T follicular helper (Tfh) cells are specialized effector CD4+ T cells required for humoral immunity. The conditional deletion of METTL3 in CD4+ T cells inhibits Tfh cell differentiation and the germinal center response in a cell-intrinsic manner. Tfh signature genes, including Tcf7, Bcl6, Icos and Cxcr5, and these effects rely on intact methyltransferase activity. Loss of METTL3 results in accelerated decay of Tcf7 transcripts, emphasizing the role of Mettl3 in stabilizing Tcf7 transcription via m6A modification and Tfh cell differentiation (100) (Figure 6B). Whether CD8+ T cells and TCR signaling in vivo are regulated by m6A requires further investigation.

**FIGURE 6**

T-cell functions were shaped by m6A regulators. (A) IL-1R is a suppressor of SOCS1 targets. The Socs family prevents STAT5 activation and downstream signaling, which are marked by m6A and show slower mRNA degradation and higher protein expression in Mettl3-deficient T helper cells and blocked signal transduction through IL-7R. (B) Loss of METTL3 in CD4+ T cells leads to the degradation of the Tfh signature gene Tcf7 and inhibits Tfh cell differentiation. (C) Mettl4 ablation in Treg cells decreases RORyt expression and blocks the differentiation of naïve T cells into Th17 cells. (D) ALKBH5 deficiency in CD4+ T cells increases the m6A modification of IFN-γ and CXCL2 mRNA, thus decreasing their mRNA stability and protein expression in CD4+ T cells.
CD4+ regulatory T (Treg) cells represent differentiated CD4+ T cells that are transcribed by Foxp3, mediate immunosuppressive function and prevent the emergence of deleterious autoimmune diseases. Treg cells express high levels of IL-2R, which activates STAT5 and is essential for their immunosuppressive function (101–103). Although in Treg-specific Mettl3 KO mice, the frequency of Treg cells was normal, both female and male developed severe autoimmune diseases and were infertile. Moreover, the mice died from 8-9 weeks and increased the mRNA levels of SOCS genes. These results suggest the important role of METTL3 in the immunosuppressive function of Treg cells (104). T-cell-specific Mettl14 deficiency induced spontaneous colitis in mice by increasing inflammatory cell infiltration, Th1/Th17 cytokines and the colonic weight-to-length ratio, which could be rescued by adoptive transfer of WT Treg cells. Mettl14-deficient Treg cells showed downregulated RORγt expression and blocked the differentiation of naïve T cells into Th17 cells (105)(Figure 6C). ALKBH5, not FTO, promotes naïve CD4+ T cells to induce adoptive transfer colitis. Additionally, T-cell-specific knockout ALKBH5 protects mice against EAE due to the increased m6A modification of interferon-γ and C-X-C motif chemokine ligand 2 (CXCL2) mRNA, thus decreasing their mRNA stability and protein expression in CD4+ T cells (Figure 6D). These changes resulted in an attenuated CD4+ T-cell response and diminished recruitment of neutrophils into the central nervous system, revealing the unexpected specific role of ALKBH5 in regulating the pathogenicity of CD4+ T cells in autoimmune disease (106). These studies highlighted some of the m6A modifiers in their therapeutic potential in antitumour and autoimmune, and it would be interesting to decipher the regulatory networks in T cells and the functions of other RNA methylations in controlling T-cell differentiation, clonal expansion and their subsequent effector functions (107).

### m6A functions in shaping the local immune microenvironment

Emerging studies have shown that the local tumor microenvironment (TME) required for tumor growth and survival plays important roles in tumor development and progression. TME is complex and contains not only cancer cells and stromal cells but also macrophages and distant recruited cells, such as infiltrating immune cells, characterized by hypoxia, immune escape, metabolic dysregulation and chronic inflammation (108, 109). m6A has been widely investigated in regulating oncogenes or tumor suppressor genes in various cancers. Accumulating studies have recently reported a new role of m6A in the antitumour immune response. In addition to affecting classical immunotherapy, m6A also affects tumor-associated immune cell activation and infiltration and cytokine secretion in the tumor microenvironment, which play important roles in tumor initiation, progression, metastasis, and treatment response (110, 111). The tumor immune microenvironment (TIME) generally consists of the infiltration of multiple immunosuppressive cells, especially MDSCs and Treg cells, and is often absent of antitumour immune cells (111, 112).

In recent years, emerging studies have deciphered the vital role of m6A modifications in the regulation of the local and systemic TIME, which mediate tumor progression and response to immunotherapy (113). The analysis of the m6A-related signatures from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and the Gene Expression Omnibus (GEO) database revealed a significant relationship between the diverse m6A clusters and the TIME (114, 115). In glioma, m6A signatures were associated with classification, including prognosis, grade, isocitrate dehydrogenase (IDH) status and 1p19q status. Patients in the high-risk group showed enhanced stroma and immune scores and a higher abundance of immune infiltration (116–119). Silencing ALKBH5 in glioblastoma multiforme (GBM) notably suppresses hypoxia-induced tumor-associated macrophage (TAM) recruitment and immunosuppression in allograft tumors by regulating CXCL8/IL-8 secretion (120). Reduced METTL3 in hepatocellular carcinoma (HCC) results in increased infiltration of DCs in the TIME, which leads to the overall upregulation of major histocompatibility complex (MHC) molecules, costimulatory molecules, and adhesion molecules and is closely related to the prognoses of HCC (121). In addition, overexpressed YTHDF1 in HCC was associated with low CD3+ and CD8+ T-cell infiltration (122). ALKBH5 regulated PD-L1 mRNA in a YTHDF2-dependent manner on monocytes/macrophages and infiltration of myeloid-derived suppressor-like cells in the TIME of intrahepatic cholangiocarcinoma (ICC) (123). Alkbh5 in melanoma and colorectal cancers (CRC) regulates the metabolism/cytokines and infiltration of immunosuppressive Treg cells and MDSCs, therefore enhancing PD-1 immunotherapy and GVAX vaccination therapy (124, 125). In addition, Alkbh5 was related to the infiltration of monocytes in periodontitis, of which regulated m6A mediated the immune reaction of TNF-family-member receptors and cytokines, indicating the crucial roles of m6A in the diversity and complexity of the immune microenvironment of periodontitis (126). Additionally, Mettl3- or Mettl14-deficient tumors upregulated cytotoxic tumor-infiltrating CD8+ T cells and increased the production of IFN-γ, Cxcl9 and Cxcl10 in the TIME of CRC in vivo, thereby enhancing the response to anti-PD-1 treatment (127). METTL3, WTP, IGF2BP3, YTHDF1, HNRNPA2B1 and HNRNPC were markedly increased in esophageal squamous cell carcinoma (ESCC) and positively related to the expression of PD-1, whose copy number dynamically affects the enrichment of tumor-infiltrating immune cells (128). Consensus clustering for 15 m6A regulators identified two molecular subtypes (clusters 1/2) in...
head and neck squamous cell carcinoma (HNSCC). Cluster 1 was enriched with G2 M checkpoint, mTORC1 signaling, and PI3K/AKT/mTOR signaling, while cluster 2 was associated with favorable prognosis, increased PD-L1, higher immune score and distinct immune cell infiltration (129). High-risk pancreatic adenocarcinoma (PAAD) contributed to the enhanced infiltration of M0 and M2 macrophages and decreased B cells, naïve T cells, CD8+ T cells and Treg cells (130–133). IGF2BPs, as functional downstream modulators of circNDUFB2, regulate the secretion of CXCL10, CXCL11, CCL5, and IFNβ in non-small cell lung cancer (NSCLC) (134, 135). In addition, m6A-related genes in peripheral blood leukocytes are noninvasive biomarkers for NCCLC patients (136). Nucleophosmin 1 (NPM1) is a chameleon protein that shuttles between the nucleus and cytoplasm. NPM1 is overexpressed in lung adenocarcinoma (LUAD) and effectively distinguishes LUAD from normal samples. The expression level of NPM1 in LUAD is markedly related to tumor stage and prognosis. Multiple database analysis showed that NPM1 is negatively related to B cells and NK cells. Moreover, NPM1 expression was significantly correlated with one m6A modifier-related gene YTHDF2 and five glycolysis-related genes (ENO1, HK2, LDHA, LDHB and SLC2A1) (137, 138). Four immune-related genes (IRGs), including CD274, CD8A, GZMA and PRF1, were screened and were consistent with the enrichment of CD8+ T cells and activated memory CD4+ T cells in the TIME of multiple cancers (132). In breast cancer, the three m6A clusters (writers, erasers and readers) are correlated with subsets of the infiltrating immune landscape, including activated CD8+ T cells, NK cells, activated DCs, macrophages and Treg cells. The low m6Ascore contributes to the increased mutation burden, immune activation and survival rates and is associated with an enhanced response to anti-PD-1/PD-L1 immunotherapy (139–141). In bladder cancer, 9 m6A-related lncRNAs were dramatically associated with overall survival outcomes of bladder cancer. The risk score of bladder cancer was correlated with the infiltration levels of multiple immune cells, including B cells, plasma cells, Tfh cells, Treg cells, resting NK cells, neutrophils, and M0, M1 and M2 macrophages, which indicated the important role of m6A-related lncRNAs in prognosis and shaping the tumor immune microenvironment (142, 143), which was also found in papillary thyroid carcinoma (PTC) (114) and HCC (144). The above studies indicated that m6A methylation and m6A-related modifications play essential roles in the differentiation and function of immune cells and secretion of cytokines, therefore shaping the TIME and further regulating the response to immunotherapy (Figure 7).
The m6A modifications in the tumor immune microenvironment have been extensively studied (Figure 8). In addition, emerging studies have reported that m6A modifications can regulate the functions of multiple immune cells and cytokine secretion and shape the TIME, thus participating in the progression of cancer. Currently, RNA modification has become a new direction for studying embryo development and maternal-fetal immune tolerance. m6A modifications in the endometrium and ovary have been reported to be related to multiple gynecological diseases, including gynecological cancers, adenomyosis, endometriosis, polycystic ovary syndrome and premature ovarian failure, which generally contribute to RPL (145, 146). Researchers have proposed that receptivity at the maternal-fetal interface is more reminiscent of cancer immunology (35, 147). Trophoblasts and tumor cells share many similarities, including invasion, angiogenesis, and immunosuppressive environments, both of which are supported by an abetting microenvironment. However, the immunosuppressive environment in tumors severely influences antitumour therapy, which is different from the decidual immune environment (147). Emerging studies of m6A in tumors have shown potential value and strengthened the functions of m6A in the decidual local immune microenvironment. The crosstalk between trophoblasts and decidual immune cells, including decidual NK cells, macrophages and T cells, determines the local immune microenvironment at the maternal-fetal interface, the imbalance of which may lead to adverse pregnancy outcomes, such as RPL/RIF and preeclampsia (148). Although little is known about m6A methylation in trophoblast and decidual immune cells, knowledge of m6A modifications in shaping multiple immune cells and the TIME would inspire us to explore the potential roles of m6A functions in maternal-fetal immune tolerance by targeting trophoblasts and decidual NK cells, T cells and macrophages as well as cytokine secretion to shape the local immune microenvironment, thus affecting placentation and immune tolerance at the maternal-fetal interface, the imbalance of which may affect placentation and disrupt the receptive microenvironment and further lead to adverse pregnancy, including RPL and RIF. However, trophoblast cells are more precisely regulated than tumor cells, and the regulatory mechanisms of m6A in trophoblast and decidual immune cells remains unknown and requires further investigation (Figure 8).

Conclusions and future perspectives

Numerous studies have elucidated the crucial roles of m6A- and m6A-associated regulators in embryogenesis during...
implantation. Additionally, other authors uncovered their essential roles in the differentiation and function of innate and adaptive immune cells as well as in shaping the local and systemic immune microenvironment. Indeed, m6A- and m6A-associated regulators target cytokine secretion and multiple immune cells in the development and metastasis of various cancers by mediating the response to immunotherapy. Interestingly, the process of blastocyst implantation was similar to the metastasis of tumors; currently, the occurrence of RIF and RPL still disturbs child-bearing age women with unknown pathologies (35, 149). It is essential to determine the potential unknown factors causing RPL and RIF to provide clear targets for reproductive physicians. Although it is relatively straightforward to diagnose RPL, the progress of predicting and preventing RPL has been hampered by a lack of a standardized definition, uncertainties around the pathogenesis and highly variable clinical presentation. Moreover, the effectiveness of many medical interventions is controversial due to the available treatments targeting the putative risk factors for RPL (150). Therefore, it is urgent to explore the underlying pathologies that lead to RPL. Dysfunction of trophoblasts, stromal cells and decidual immune cells contributes to RPL and RIF. The m6A- and m6A-related-regulators participate in embryogenesis and shape the local microenvironment, which draws inspiration from studies in tumors and provides novel insight for investigating the potential pathologies causing RPL and RIF. Although some studies have reported the role of m6A- and m6A-related-regulators in the function of trophoblasts and are therefore correlated with pathological pregnancies, the relationship between m6A-and m6A-related-regulators and maternal decidual cells and the local immune microenvironment at the maternal-fetal interface is still unknown and needs further exploration, which would fill the gap in m6A in the shaping microenvironment at the maternal-fetal interface.

Author contributions

HL: conceptualization, investigation, data curation, writing – original draft, visualization, funding acquisition. JZ: data curation, writing – review & editing. AL: conceptualization, writing – review & editing. All authors have read and approved the final manuscript.

Funding

This work is supported by the Women and Children’s Hospital of Hubei Province (2021SYFY002).

Acknowledgments

We thank Kahinho P Muyayalo and Zhijing Zhang for the language editing. The figures in this paper were created with BioRender.com.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 499:57–74. doi: 10.1038/nature12477

2. Li S, Mason CE. The pivotal regulatory landscape of RNA modifications. Annu Rev Genomics Hum Genet (2014) 15:127–50. doi: 10.1146/annurev-genom-090413-025405

3. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell (2017) 169:1187–200. doi: 10.1016/j.cell.2017.05.045

4. Aguiló F, Walsh MJ. The N(6)-methyladenosine RNA modification in pluripotency and reprogramming. Curr Opin Genet Dev (2017) 46:77–82. doi: 10.1016/j.gcd.2017.06.006

5. Yu F, Wei J, Cui X, Yu C, Ni W, Bungett J, et al. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res (2021) 49:5779–97. doi: 10.1093/nar/gkab415

6. An S, Huang W, Huang X, Cun Y, Cheng W, Sun X, et al. Integrative network analysis identifies cell-specific trans regulators of m6A. Nucleic Acids Res (2020) 48:1715–29. doi: 10.1093/nar/gkaa1206

7. Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol (2017) 18:31–42. doi: 10.1038/nrm.2016.132

8. Shulman Z, Stern-Ginossar N. The RNA modification N(6)-methyladenosine as a novel regulator of the immune system. Nat Immunol (2020) 21:501–12. doi: 10.1038/s41590-020-0650-4

9. Grozhik AV, Linder B, Olarerin-George AO, Jaffrey SR. Mapping m(6)A at individual-nucleotide resolution using crosslinking and immunoprecipitation (miCLIP). Methods Mol Biol (2017) 1562:55–78. doi: 10.1007/978-1-4939-6807-7_5

10. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods (2015) 12:767–72. doi: 10.1038/nmeth.3453

11. Ke S, Alemu EA, Mertens C, Gantman EC, Fak JJ, Mele A, et al. A majority of m6A residues are in the last exons, allowing the potential for 3’ UTR regulation. Genes Dev (2015) 29:2037–53. doi: 10.1101/gad.264915.115

12. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol (2019) 20:608–24. doi: 10.1038/s41580-019-0168-5

13. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol (2014) 10:93–5. doi: 10.1038/nchembio.1432
Structures of human ALKBH5 demethylase reveal a unique binding mode for mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Genes Dev.

Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-Mettl3 and Mettl14 methyltransferases.

aspects of pregnancy.

RNA m(6)A methylation and mouse embryonic stem cell self-renewal. Mol Cell.

methylation at internal and 5'UTR. Genes Dev.

The placental immune milieu is characterized by a Th2- and anti-inflammatory transcription profile, regardless of maternal allergy, and associates with neonatal immunity. Am J Reprod Immunol (2015) 73:445–59. doi:10.1111/ajr.12350

Cakmak H, Taylor HS. Implantation failure: molecular mechanisms and clinical treatment. Hum Reprod Update (2017) 13:242–53. doi:10.1093/humupd/ dmp037

Sui X, Hu Y, Ren C, Cao Q, Zhou S, Cao Y, et al. METTL3-mediated m6A is required for murine oocyte maturation and maternal-to-zygotic transition. Cell (2019) 179:189–101.e11. doi:10.1016/j.cell.2018.08.004

Zhao BS, Wang X, Beadell AV, Lu Z, Shi H, Kuapolua A, et al. m6A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. Nature (2017) 542:475–8. doi:10.1038/nature19355

Du H, Zhao Y, He J, Zhang Y, XH, Li M, et al. YTHDF2 destabilises m6A-containing RNA through direct recruitment of the CCRA-NOT deadenylase complex. Nat Commun (2016) 7:12626. doi:10.1038/ncomms12626

Fang F, Wang X, Li Z, Ni K, Xiong C. Epigenetic regulation of mRNA N6-methyladenosine modifications in mammalian gametogenesis. Mol Hum Reprod (2021) 27:gaao0025.36. doi:10.1038/s41362-021-01023-3

Song P, Tayyar S, Cai Z, Jia G. RNA Methylation in mammalian development and cancer. Cell Biol Toxicol (2021) 37:811–31. doi:10.1007/s12015-021-09676-8

Zheng M, Zhao Y, Zhang S, Dai X, Li Z. Roles of N6-methyladenosine (m6A) in stem cell fate decisions and early embryonic development in mammals. Front Cell Dev Biol (2020) 8:792. doi:10.3389/fcell.2020.00782

Xu W, Li J, He C, Wen J, Ma H, Rong B, et al. METTL3 regulates heterochromatin in mouse embryonic stem cells. Nature (2021) 591:317–21. doi:10.1038/s41586-021-03210-1

Kwon J, Yu Y, Namoogang S, Kim YH. Functional roles of histRNA2/B2 regulated by METTL3 in mammalian embryonic development. Sci Rep (2019) 9:8640. doi:10.1038/s41598-019-44714-1

Liu W, Wang H, Zhao X, Luo Q, Wang Y, Tan K, et al. Arginine methylation of METTL14 promotes RNA N6(methyladenosine)-mediated endo marking and endo marking of mouse embryonic stem cells. Nat Commun (2021) 12:3780. doi:10.1038/s41467-021-24035-6

Hao J, Huang S, Wang D, Jin Y, Zhang M, Zhang J, et al. Loss of WTAP impairs early parthenogenetic embryo development. Ani Sci (2021) 11:675–84. doi:10.3390/ani11061675

Despic V, Dejung M, Gu M, Krishnan J, Zhang H, Herzel L, et al. Dynamic RNA protein interactions underlie the zebrafish maternal-to-zygotic transition. Genome Res (2017) 27:1184–90. doi:10.1101/gr.215954.116

Ivanova I, Much C, Di Giacomio M, Azzi C, Morgan M, Moreira PN, et al. The RNA m6A reader YTHDF2 is essential for the post-transcriptional regulation of the maternal transcriptome and oocyte competence. Mol Cell (2017) 67:1059–1067.e4. doi:10.1016/j.molcel.2017.08.003

Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, et al. VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discovery (2018) 4:10. doi:10.1038/s41421-018-0019-0

Chen X, Zhao Q, Zhao YL, Chai GS, Cheng W, Zhao Z, et al. Targeted RNA N6(methyladenosine) demethylation controls cell fate transition in human pluripotent stem cells. Adv Sci (Weinh) (2019) 6:e2003902. doi:10.1002/advs.202003902

Hao J, Hu H, Jiang Z, Yu X, Li C, Chen L, et al. microRNA-670 modulates Igf2bp1 expression to regulate RNA methylation in parthenogenetic mouse embryonic development. Sci Rep (2020) 10:4782. doi:10.1038/s41598-020-61816-3

Liu HB, Muhammad T, Quo Y, Li MJ, Sha QQ, Zhang CX, et al. RNA-Binding protein Igf2bp2/Imp2 is a critical maternal activator in early zygotic genome activation. Adv Sci (Weinh) (2019) 6:1900295. doi:10.1002/advs.201900295

Ren F, Lin Q, Gong G, Du X, Han D, Qin W, et al. Igf2bp3 maintains maternal RNA stability and ensures early embryo development in zebrafish. Commun Biol (2020) 3:94. doi:10.1038/s42003-020-0827-2

ProthabDas M, Bonney E, Carson K, Dey S, Erlebacher A, Fazleabas A, et al. Immune mechanisms at the maternal-fetal interface: perspectives and challenges. Nat Immunol (2015) 16:328–34. doi:10.1038/nri.3311

Yang F, Zheng Q, Jin L. Dynamic function and composition changes of immune cells during normal and pathological pregnancy at the maternal-fetal interface. Front Immunol (2019) 10:2317. doi:10.3389/fimmu.2019.02317

Abelius MS, Janeford C, Ernordhi J, Berg G, Matthiesen L, Duchen K, et al. The placental immune milieu is characterized by a Th2- and anti-inflammatory transcription profile, regardless of maternal allergy, and associates with neonatal immunity. Am J Reprod Immunol (2015) 73:445–59. doi:10.1111/ajr.12350
Adaptive immunity in secondary lymphoid tissue.

Meng TG, Lu X, Guo L, Hou GM, Ma Xs, Li QN, et al. Mettl14 is required for mouse postimplantation development by facilitating epiblast maturation. *FASEB J* (2019) 33:1179–87. doi: 10.1096/fj.201801719r

Shima H, Matsumoto M, Igishami Y, Ebina M, Muto A, Sato Y, et al. S-adenosylmethionine synthesis is regulated by selective N6-adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. *Cell Rep* (2017) 23:1353–64. doi: 10.1016/j.celrep.2017.11.092

Fukushima Y, Naruse C, Asano M. Wtp is required for differentiation of endoderm and mesoderm in the mouse embryo. *Dev Dyn* (2008) 237:618–29. doi: 10.1002/dvdy.21444

Kawazoe SD, Ma J, Anderson SJ, Leu NA, Xu Y, Gregory RD, et al. Nuclear m6A promotes alternative polyadenylation and splicing during mouse oocyte development. *PloS Genet* (2018) 14:e1007412. doi: 10.1371/journal.pgen.1007412

Perez-Garcia Y, Fineberg E, Wilson R, Murray A, Mazzeo CJ, Tudor C, et al. Placental defects are highly prevalent in embryonic lethal mouse mutants. *Nature* (2018) 555:468–3. doi: 10.1038/nature26002

Gu Y, Chu X, Morgan JA, Lewis DF, Wang Y. Upregulation of METTL3 expression and mRNA methylation in placental trophoblasts in preeclampsia. *Am J Reprod Immunol* (2021) 86:102. doi: 10.1111/ajri.13085

Li R, Qiu X, He M, Qiao J, He J, Zhong M. METTL3-mediated mature miR-497-5p/195-5p inhibits trophoblast migration and invasion by targeting mTORC1. *Environ Toxicol* (2021) 37:910–24. doi: 10.1002/tox.24354

Li XC, Jin F, Wang RY, Yin XJ, Hong W, Tian FJ. The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of CRB1 mRNA. *Theranostics* (2019) 9:3853–65. doi: 10.7150/thno.31868

Tang L, Wei X, Li T, Chen Y, Dai Z, Lu C, et al. Emerging perspectives of RNA n(6)-methyladenosine (m(6)A) modification on immunity and autoimmune diseases. *Front Immunol* (2021) 12:630358. doi: 10.3389/fimmu.2021.630358

Qi H, Kastenmuller W, Germain RN. Spatiotemporal basis of innate and adaptive immunity and the continued thymic activity. *Front Immunol* (2017) 8:218.e20210279. doi: 10.3389/fimmu.2021.02149

Gu H, Zang Y, Yang P, Zhang X, Peng Y, Li D, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. *Nat Commun* (2021) 12:1394. doi: 10.1038/s41467-021-21541-8

Qin Y, Li B, Arumugam S, Lu Q, Mankash SM, Li J, et al. m6A mRNA methylation-directed myeloid cell activation controls progression of NAPLD and obesity. *Cell Rep* (2021) 37:10996. doi: 10.1016/j.celrep.2021.109968

Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J, et al. The loss of RNA n(6)-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8(+) T cell dysfunction and tumor growth. *Cancer Cell* (2019) 33:945–957.e10. doi: 10.1016/j.ccell.2019.04.016

Gu X, Zhang Y, Li D, Cai H, Cai X, Xu Q. N(6)-methyladenosine demethylation FTO promotes M1 and M2 macrophage activation. *Cell Signal* (2020) 69:109553. doi: 10.1016/j.cellsig.2020.10.016

Liu Y, Liu Z, Tang H, Shen Y, Gong Z, Xie N, et al. The n(6)-methyladenosine (m(6)A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STA1 mRNA. *Am J Physiol Cell Physiol* (2019) 317:C762–75. doi: 10.1152/ajpcell.00212.2019

Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J, et al. The loss of RNA n(6)-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8(+) T cell dysfunction and tumor growth. *Cancer Cell* (2019) 33:945–957.e10. doi: 10.1016/j.ccell.2019.04.016

Qi H, Kastenmuller W, Germain RN. Spatiotemporal basis of innate and adaptive immunity and the continued thymic activity. *Front Immunol* (2017) 8:218.e20210279. doi: 10.3389/fimmu.2021.02149

Xing Y, Cheng D, Shi C, Shen Z. The protective role of YTHDF1 knock down macrophages on the immune paralysis of severe sepsis rats with ECMO. *Microb Res* (2021) 237:104179. doi: 10.1016/j.micres.2021.104179

Fang C, He M, Li D, Xu Q. YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-kappaB and MAPK signaling pathways. *Cell Signal* (2021) 85:110060. doi: 10.1016/j.cellsig.2021.110060

Wang X, Li J, Feng P, Liu R, Li G, Zheng J, et al. The m6A reader IGF2BP2 regulates macrophage phenotypic activation and inflammatory diseases by stabilizing TSC1 and PPARGamma. *Adv Sci (Weinh)* (2021) 8:210209. doi: 10.1002/advs.20210209

Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang LS, et al. The RNA m6A reader YTHDF2 controls NK cell antimur and antiviral immunity. *J Exp Med* (2021) 218.e2102079. doi: 10.1084/jem.202102079

Song H, Song J, Cheng M, Zheng M, Wang T, Sian T, et al. METTL3-mediated mRNA methylation promotes the anti-tumour immunity of natural killer cells. *Nat Commun* (2021) 12:5522. doi: 10.1038/s41467-021-25803-0

Silva SL, Albuquerque AS, Matsuo P, Charnay-Meslier B, Cherynier R, Liger D, et al. IL-7-induced proliferation of human naive CD4 T-cells relies on continued thymic activity. *Front Immunol* (2017) 8:230. doi: 10.3389/fimmu.2017.00200

Li HB, Tong J, Zhu S, Bataia PJ, Duffy EE, Zhao J, et al. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. *Nature* (2017) 548:338–42. doi: 10.1038/nature23450

Tan JT, Dudd E, Leffoy E, Murray R, Sprent J, Weinberg KI, et al. IL-7 is critical for hematopoietic proliferation and survival of naive T cells. *Proc Natl Acad Sci U.S.A.* (2001) 98:8732–7. doi: 10.1073/pnas.0116209

Seki Y, Yang J, Okamoto M, Tanaka S, Goitsuka R, Farrar MA, et al. IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. *J Immunol* (2007) 178:262–70. doi: 10.4049/jimmunol.178.1.262

Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. *Trends Immunol* (2009) 30:592–602. doi: 10.1016/j.it.2009.09.009

Yao Y, Yang Y, Guo W, Xu Y, Liu M, Yang YC, et al. METTL3-dependent m6A modification programs T follicular helper cell differentiation. *Nat Commun* (2021) 12:1335. doi: 10.1038/s41467-021-21594-6

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *Immunity* (1995) 3:587–604. doi: 10.1016/0890-8125(95)00030-2

Liu CW, Hsieh CS. A two-step process for thymic regulatory T cell development. *Immunology* (2008) 28:100–11. doi: 10.1016/j.immuni.2007.11.021
prognostic regulators in adrenocortical carcinoma. 

Front Immunol (2018) 9:1501. doi: 10.3389/fimmu.2018.01501

Tong J, Cao G, Zhang T, Sefik E, Amezcu Vesely MC, Broughton JP, et al. mi(6)A mRNA methylation sustains treg suppressive functions. Cell Res (2018) 28:23–6. doi: 10.1038/cr.2017.87

Lu TX, Zheng Z, Zhang L, Sun HL, Bosinnetone M, Huang H, et al. A new model of spontaneous colitis in mice induced by deletion of an RNA m(6)A methyltransferase component METTL14 in T cells. Cell Mol Gastroenterol Hepatol (2020) 10:747–61. doi: 10.1016/j.jcmgh.2020.07.001

Zhou J, Zhang S, Xu J, Qi R, Yu Z, Xu H, et al. m(6)A demethylase ALKBH5 regulates CD4+ T cell pathogenesis and promotes autoimmunity. Sci Adv (2021) 7:eabg0470. doi: 10.1126/sciadv.abg0470

Chao Y, Li HB, Zhou J. Multiple functions of RNA methylation in T cells: A review. Front Immunol (2021) 12:627455. doi: 10.3389/fimmu.2021.627455

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer (2020) 19:53. doi: 10.1186/s12943-020-01170-0

Gu Y, Wu X, Zhang J, Fang Y, Pan Y, Shu Y, et al. The evolving landscape of m(6)A-mediated messenger RNA methylation and neutrophil extracellular traps (NETs)-mediated collective tumor invasion. Biofabrication (2021) 13:10.1088/1758-5090/abe1cf

Binnweiler M, Roberts EW, Kersten K, Chan V, Fearn D, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med (2018) 24:541–10. doi: 10.1038/s41591-018-0014-x

Berger Y, Giurcancun M, Vining CC, Schuetteendor D, Posner MC, Roggin KK, et al. Cyto Reductive surgery for selected patients whose metastatic gastric cancer was treated with systemic chemotherapy. Ann Surg Oncol (2021) 28:4333–43. doi: 10.1245/s10434-020-09475-6

Guo L, Yang H, Zhou C, Shi Y, Huang L, Zhang J. N6-methyladenosine RNA modification in the tumor immune microenvironment: Novel implications for immunotherapy. Front Immunol (2021) 12:773570. doi: 10.3389/fimmu.2021.773570

Tang R, Zhang Y, Liang C, Xu J, Meng Q, Hua J, et al. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. Perif (2020) 8:e9602. doi: 10.7177/perif.9602

Jin Y, Yang W, Zhang H, He D, Zou Y, Hu X, Gong L, et al. Analysis of m6A-regulated signatures in the tumor immune microenvironment and identification of clinical prognostic regulators in adrenocortical carcinoma. Front Immunol (2021) 12:637933. doi: 10.3389/fimmu.2021.637933

Xu S, Tang L, Dai G, Luo C, Liu Z. Expression of m6A regulators correlated with immune microenvironment predicts therapeutic efficacy and prognosis in gliomas. Front Cell Dev Biol (2020) 8:949112. doi: 10.3389/fcell.2020.0949112

Lin S, Xu H, Zhang A, Ni Y, Xu Y, Meng T, et al. Prognosis analysis and validation of m6A signature and tumor immune microenvironment in glioma. Front Oncol (2020) 10:541401. doi: 10.3389/fonc.2020.541401

Du J, Ji J, Hu M, Jin J, Mi S, Hou K, et al. m6A regulator-mediated methylation modulation patterns and characteristics of immunity and stemness in low-grade glioma. Brief Bioinform (2021) 22:bbab013. doi: 10.1093/bib/bbab013

Liu W, Li C, Wu X, Wu X, Chen S, Zhang H, et al. Integrating m6A regulators-mediated methylation modification models and tumor immune microenvironment characterization in Caucasian and Chinese low-grade gliomas. Front Cell Dev Biol (2021) 9:725764. doi: 10.3389/fcell.2021.725764

Dong F, Qin X, Wang B, Li Q, Hu J, Chen X, et al. ALKBH5 facilitates hypoxia-induced paracaspase assembly and IL8 secretion to generate an immunosuppressive microenvironment. Cancer Res (2021) 81:5876–88. doi: 10.1158/0008-5472.CAN-21-4546

Shen S, Yan J, Zhang Y, Dong Z, Xing J, He Y. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment predict the prognosis of hepatocellular carcinoma. Ann Trans Med (2021) 9:59. doi: 10.21037/atm-20-7396

Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, et al. m6A regulator-associated modification patterns and immune infiltration of the tumor microenvironment in hepatocarcinoma. Front Cell Dev Biol (2021) 9:688756. doi: 10.3389/fcell.2021.688756

Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, et al. m(6)A demethylase ALKBH5 regulates PD-L1 expression and tumor immuneinvolvement in intrathepatic cholangiocarcinoma. Cancer Res (2021) 81:4778–93. doi: 10.1158/0008-5472.CAN-21-0468
144. Li L, Xie R, Lu G. Identification of m6A methyltransferase-related IncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. *Biosci Rep* (2021) 41:BSR20210760. doi: 10.1042/BSR20210760

145. Zhai J, Li S, Sen S, Opoku-Anane J, Du Y, Chen ZJ, et al. m(6)A RNA methylation regulators contribute to eutopic endometrium and myometrium dysfunction in adenomyosis. *Front Genet* (2020) 11:746. doi: 10.3389/fgene.2020.00746

146. Chen J, Fang Y, Xu Y, Sun H. Role of m6A modification in female infertility and reproductive system diseases. *Int J Biol Sci* (2022) 18:3592–604. doi: 10.7150/ijbs.69771

147. Krstic J, Deutsch A, Puchi J, Gauster M, Gorsiek Sparovec T, Hiden U, et al. (Dis)similarities between the decidual and tumor microenvironment. *Biomedicines* (2022) 10:1065. doi: 10.3390/biomedicines10051065

148. Wang XQ, Li DJ. The mechanisms by which trophoblast-derived molecules induce maternal-fetal immune tolerance. *Cell Mol Immunol* (2020) 17:1204–7. doi: 10.1038/s41423-020-0460-5

149. Franasiak JM, Aleksandru D, Forman EJ, Gemmell LC, Goldberg JM, Llarena N, et al. A review of the pathophysiology of recurrent implantation failure. *Fertil Steril* (2021) 116:1436–48. doi: 10.1016/j.fertnstert.2021.09.014

150. Dimitriadis E, Menkhorst E, Saito S, Kuttel WH, Brosens J. Recurrent pregnancy loss. *Nat Rev Dis Primers* (2020) 6:98. doi: 10.1038/s41572-020-00228-z